USD 0.3
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2024 | - CAD | 0.0% |
2023 | - CAD | 0.0% |
2022 | - CAD | 0.0% |
2021 | - CAD | 0.0% |
2020 | - CAD | 0.0% |
2019 | - CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 FY | - CAD | 0.0% |
2024 Q4 | - CAD | 0.0% |
2024 Q3 | - CAD | 0.0% |
2024 Q2 | - CAD | 0.0% |
2024 Q1 | - CAD | 100.0% |
2023 Q3 | - CAD | -100.0% |
2023 Q4 | -5541.00 CAD | 0.0% |
2023 Q1 | - CAD | 0.0% |
2023 FY | - CAD | 0.0% |
2023 Q2 | 5541.00 CAD | 0.0% |
2022 FY | - CAD | 0.0% |
2022 Q3 | - CAD | 0.0% |
2022 Q2 | - CAD | 0.0% |
2022 Q1 | - CAD | 0.0% |
2022 Q4 | - CAD | 0.0% |
2021 FY | - CAD | 0.0% |
2021 Q4 | - CAD | 0.0% |
2021 Q2 | - CAD | 0.0% |
2021 Q3 | - CAD | 0.0% |
2021 Q1 | - CAD | 0.0% |
2020 FY | - CAD | 0.0% |
2019 FY | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
AstraZeneca PLC | 46.91 Billion USD | 100.0% |
Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | 100.0% |
CSPC Pharmaceutical Group Limited | 31.45 Billion USD | 100.0% |
Clarus Therapeutics Holdings, Inc. | 13.95 Million USD | 100.0% |
Novartis AG | 46.66 Billion USD | 100.0% |
PT Kalbe Farma Tbk. | 1.97 Billion USD | 100.0% |